Clinical trial · Observational
Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Non-Small Cell Lung Cancer And Bronchial Disease
Immunobiology of Photodynamic Therapy in Lung Cancer Patients
NCT00754910CI-TRIAL-00033617completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, cancer cells are killed. This may be effective against non-small cell lung cancer. PURPOSE: This clinical trial is studying how well photodynamic therapy using porfimer sodium works in treating patients with non-small cell lung cancer and bronchial disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bronchoscopy | Procedure | — | UNRESOLVED |
| porfimer sodium | Drug | Porfimer | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Group 1
- description
- Patients receive porfimer sodium IV over 3-5 minutes and undergo irradiation with red light 48 hours later. Patients receive 2 more treatments at 2-day intervals.
- interventionNames
- Drug: porfimer sodium
- Procedure: bronchoscopy
Primary outcomes (1)
- measure
- Determine the cytokine phenotype found in collected specimens of lung cancer patients treated with photodynamic therapy.
- timeFrame
- up to one year
- description
- Tumor tissue, broncheoalveolar fluid and blood from enrolled patients will be assayed for the presence of the following defined lymphocyte phenotypes
Secondary outcomes (1)
- measure
- Correlate the cytokine phenotype of patients undergoing PDT treatment with survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients that have a diagnosis of non-small cell lung cancer, of any stage, with obstructive or hemorrhagic endobronchial disease receiving PDT treatment. Exclusion Criteria: * Patients that have undergone PDT, chemotherapy or radiation therapy within the past 3 months will not be considered for enrollment. * Patients taking antioxidant therapy will be excluded from enrollment due to potential interaction with the potential oxidative mechanism of action of Photofrin®. These antioxidants would include beta-carotene, lutein, Lycopene, Selenium, Vitamin A, Vitamin C, Vitamin E.
References
Publications (0)
Data not yet available
No reference posted for this study.